Kalpress (Valsartan)

• Valsartan is used in cardiovascular conditions that involve the renin‑angiotensin system.
• Hypertension: reduces systolic and diastolic blood pressure, improving overall cardiovascular risk profile.
• Heart failure: decreases morbidity and mortality by lowering ventricular workload and preventing adverse remodeling.
• Left ventricular dysfunction after myocardial infarction: improves cardiac function and reduces the risk of subsequent heart failure.

• Valsartan selectively blocks the angiotensin II type 1 (AT₁) receptor, preventing angiotensin II from binding and activating the receptor. This inhibition stops vasoconstriction, aldosterone secretion, and sympathetic stimulation, leading to vasodilation, reduced sodium and water retention, and lower blood pressure. The blockade also attenuates pathological cardiac remodeling associated with chronic hypertension and heart failure. By maintaining a more favorable hemodynamic profile, Valsartan contributes to long‑term protection of the cardiovascular system.

Valsartan may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after the first doses or dose changes.
• Headache: mild to moderate head pain occurring intermittently.
• Fatigue: feeling unusually tired or lacking energy.
• Hyperkalemia: elevated blood potassium levels detected in routine labs.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue or airway requiring immediate medical attention.
• Acute renal impairment: sudden decrease in kidney function, manifested by rising creatinine.
• Severe hypotension: marked drop in blood pressure leading to fainting or shock.

When prescribing Valsartan, clinicians should consider several precautionary measures to ensure patient safety.

• Renal function monitoring: assess serum creatinine and eGFR before initiation and periodically during therapy.
• Electrolyte assessment: check potassium levels regularly, especially when combined with potassium‑sparing agents.
• Pregnancy contraindication: avoid use during pregnancy due to risk of fetal toxicity; discontinue promptly if pregnancy occurs.
• Concomitant ACE inhibitor use: do not combine with ACE inhibitors; increase risk of angioedema and renal dysfunction.
• Volume depletion: caution in patients with dehydration or on high‑dose diuretics to prevent hypotension.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Valsartan can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• ACE inhibitors: combined use markedly raises the risk of angioedema and renal impairment.
• Aliskiren (in diabetics): co‑administration can cause severe renal dysfunction and hyperkalemia.
• Potassium‑sparing diuretics or supplements: may lead to dangerous hyperkalemia.

Moderate Interactions (Monitor Closely)

• NSAIDs: can reduce antihypertensive effect and worsen renal function.
• Loop or thiazide diuretics: may enhance hypotensive response; monitor blood pressure.
• Lithium: Valsartan may increase lithium concentrations, requiring serum level checks.